What are the limitations of the thalassaemia transfusion?

While the thalassaemia transfusion is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the thalassaemia transfusion to ensure safe bedside use and optimal diagnostic accuracy.

How does the thalassaemia transfusion compare to other hematology scores?

The thalassaemia transfusion is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the thalassaemia transfusion free to use?

Yes. OpiCalc provides the thalassaemia transfusion completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

Thalassaemia Transfusion Threshold

Thalassaemia Management: Distinguishing Transfusion-Dependent (TDT) from Non-Dependent (NTDT) forms. TDT requires suppression of ineffective erythropoiesis.

Baseline Haemoglobin (g/dL)

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Transfusion-Dependent Thalassaemia (TDT)

Baseline haemoglobin (Hb) < 7 g/dL confirmed on two occasions (separated by > 2 weeks).

Hb > 7 g/dL with significant clinical features (poor growth, facial bone changes, significant organomegaly).

To suppress endogenous erythropoiesis and prevent extramedullary expansion.

Non-Transfusion-Dependent Thalassaemia (NTDT)

Patients with Hb 7–10 g/dL who usually maintain acceptable growth but may require "episodic" transfusion during pregnancy or infection.

Section 2

Formula & Logic

Hb Targets (TDT)

Parameter	Target Range
Pre-transfusion Hb	9.5 - 10.5 g/dL
Post-transfusion Hb	14.0 - 15.0 g/dL
Mean Hb	12.0 g/dL

Transfusion Frequency

Typically every 2–4 weeks using leucodepleted, phenotypically matched RBCs (at minimum C, E, and K matching).

Section 3

Pearls/Pitfalls

Avoiding the "Hb 7" Trap

In TDT, waiting for Hb to drop < 7 g/dL can lead to irreversible bone marrow expansion and skeletal deformities. The goal is "Hypertransfusion" (maintaining Hb > 9.5) to keep erythropoietin levels low.

Alloimmunization

Patients with thalassaemia are at high risk for alloimmunization. Extended phenotypic matching and monitoring for delayed haemolytic transfusion reactions (DHTR) are essential.

Section 4

Evidence Appraisal

Primary Guidelines

Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT).

Cappellini MD et al. • TIF Publications. 2021;4th Edition.

View Source

Section 5

Literature

Philosophy

Developed by the TIF to standardize global care, ensuring that even in resource-limited settings, the biological principles of marrow suppression are upheld to prevent long-term morbidity.

Last Comprehensive Review: 2026

Related Hematology Tools

AL Amyloidosis Staging

HCT-CI

EBMT Risk Score

DRI

MAGIC aGvHD Biomarker Score

CRS Grading

ICANS Grading

aGvHD Grading

NIH Chronic GvHD Scoring

Sickle Cell Disease Risk

Have feedback about this calculator?Let us know.